Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: Sickle Cell Disease
Interventions: Ticagrelor, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Miami, Florida • Bethesda, Maryland • Charleston, South Carolina

Conditions: Leukemia, Myeloid, Acute
Interventions: Vosaroxin and Cytarabine; Drug
Lead sponsor: Hamid Sayar; Other
Eligibility: 60 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: GTI-2040, pharmacological study, laboratory biomarker analysis; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Duarte, California

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions: Biospecimen collection, Data collection; Other
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: Alcohol Use Disorder
Interventions: LY3537031, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Meningococcal Infections, Meningococcal Meningitis
Interventions: MenACWY CRM, Meningococcal ACWY Conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 55 Years
Enrollment: 3,539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Fremont, California + 37 more

Conditions: ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions: Centanafadine, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 46
States / cities: Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more

Conditions: Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions: Ascorbate, Gemcitabine; Drug
Lead sponsor: Mohammed Milhem, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hookworm Infections
Interventions: Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum; Biological · Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Autism Spectrum Disorder
Interventions: Healthy Habits for Life; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 26 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
Interventions: CEST-MRF; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioma
Interventions: bevacizumab, carmustine; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Interventions: PF-08046054, Docetaxel monotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 262
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 177 more

Conditions: Osteoarthritis, Knee
Interventions: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function, Muscle biopsies, Determination of 1 Repetition Maximum (1-RM), Blood flow restriction exercise, Borg CR10 scale; Device · Behavioral · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 55 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes Mellitus, Type 1
Interventions: Resilient, Empowered, Active Living-Telehealth (REAL-T); Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 30 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions: Rimegepant, Zavegepant; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hearing Loss
Interventions: Clinically Streamlined and Structured Aural Rehabilitation (CSSAR); Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 55 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV-1-infection, Hepatitis B
Interventions: B/F/TAF; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Brain Neoplasms, Central Nervous System Neoplasms
Interventions: TPI287, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: SCORE Intervention; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dementia
Interventions: Experimental: Intervention 1 (AB): Engagement in Motion-Based Activities (Wii & Magic Table), Experimental: Intervention 2 (BA): Engagement in Motion-Based Activities (Magic Table BA); Other
Lead sponsor: Midwestern University; Other
Eligibility: 21 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Downers Grove, Illinois

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Tazbentetol; Drug
Lead sponsor: Spinogenix; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 16
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more

Conditions: Alzheimers Disease
Interventions: No Intervention; Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nutley, New Jersey

Search by objective public record fields.

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

A Study of Brenipatide in Participants With Alcohol Use Disorder

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Gemcitabine Plus Ascorbate for Sarcoma in Adults

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Blood Flow Restriction Exercise Study

Evaluation of an Intervention for Young Adults With Diabetes: Resilient, Empowered, Active Living-Telehealth (REAL-T)

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

Benefit of a Clinically Streamlined and Structured Aural Rehabilitation (CSSAR) Program in Adults

B/F/TAF Switch Study for HIV-HBV Coinfection

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia

Increasing Engagement and Positive Emotional Behavior of Older Adults With Mild-Moderate Dementia With the Use of Motion-Based Technology and Meaningful Activities

Intermediate-size Patient Population Expanded Access Protocol

A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease